Referencia número: HY-106161

Rupintrivir

(Synonyms: AG7088)

7 Cited Publications

Revisión del cliente

Based on 7 publication(s) in Google Scholar

Rupintrivirvr (AG7088), an antiviral agent, is a potent, selective and irreversible inhibitor of human rhinovirus (HRV) 3C protease. Rupintrivirvr inhibits replication of a panel of 48 different HRV serotypes in H1-HeLA and MRC-5 cell protection assays, with a mean EC₅₀ of 0.023 μM. Rupintrivirvr shows immune-modulatory effect.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.0%
No. CAS: 223537-30-2
Fòrmula: C₃₁H₃₉FN₄O₇
Peso molecular:598.66

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Rupintrivir Chemical Structure

No. CAS: 223537-30-2

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (7)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Bioz

Actividad biológica

Descripciòn

Cellular Effect

Cell Line	Type	Value	Description	References
H1-HeLa	EC₅₀	14 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HRV14 with 3C protease T129A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	14 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T131A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HRV14 with 3C protease T131A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	14 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease Y139H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HRV14 with 3C protease Y139H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	140 nM Compound: AG-7088	Antiviral activity against HRV2 with 3C protease E3E/G, A103A/V, N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 62 days by XTT assay Antiviral activity against HRV2 with 3C protease E3E/G, A103A/V, N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 62 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	15 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HRV14 with 3C protease T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	152 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129T/A, T131T/A, T143P/S mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 14 days by XTT assay Antiviral activity against HRV14 with 3C protease T129T/A, T131T/A, T143P/S mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 14 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	19 nM Compound: AG-7088	Antiviral activity against wild type HRV Hanks infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 days by plaque reduction assay Antiviral activity against wild type HRV Hanks infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 days by plaque reduction assay	[PMID: 17908951]
H1-HeLa	EC₅₀	21 nM Compound: AG-7088	Antiviral activity against wild type HRV14 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against wild type HRV14 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	227 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 17 days by XTT assay Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 17 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	24 nM Compound: AG-7088	Antiviral activity against wild type HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against wild type HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	268 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129A, T131A, Y139H, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HRV14 with 3C protease T129A, T131A, Y139H, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	30 nM Compound: AG-7088	Antiviral activity against wild type HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay Antiviral activity against wild type HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	324 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 10 passages for 55 days by XTT assay Antiviral activity against HRV14 with 3C protease T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 10 passages for 55 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	335 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease A121A/V, T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 11 passages for 65 days by XTT assay Antiviral activity against HRV14 with 3C protease A121A/V, T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 11 passages for 65 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	34 nM Compound: AG-7088	Antiviral activity against HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 17 days by XTT assay Antiviral activity against HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 17 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	414 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease A121A/V, T129A, T131A, N132S, Y139Y/H, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 12 passages for 72 days by XTT assay Antiviral activity against HRV14 with 3C protease A121A/V, T129A, T131A, N132S, Y139Y/H, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 12 passages for 72 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	44 nM Compound: AG-7088	Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 24 days by XTT assay Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 24 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	51 nM Compound: AG-7088	Antiviral activity against HRV Hanks with 3C protease T130A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 40 days by plaque reduction assay Antiviral activity against HRV Hanks with 3C protease T130A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 40 days by plaque reduction assay	[PMID: 17908951]
H1-HeLa	EC₅₀	57 nM Compound: AG-7088	Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 30 days by XTT assay Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 30 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	67 nM Compound: AG-7088	Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 37 days by XTT assay Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 37 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	83 nM Compound: AG-7088	Antiviral activity against HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 29 days by XTT assay Antiviral activity against HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 29 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	94 nM Compound: AG-7088	Antiviral activity against HRV39 with 3C protease S105T, N130K, L136F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 50 days by XTT assay Antiviral activity against HRV39 with 3C protease S105T, N130K, L136F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 50 days by XTT assay	[PMID: 17908951]
H1-HeLa	EC₅₀	96 nM Compound: AG-7088	Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 22 days by XTT assay Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 22 days by XTT assay	[PMID: 17908951]
H1-HeLa	CC₅₀	>100 μM Compound: Rupintrivir	Cytotoxicity against human H1-HeLa cells infected with 1 MOI human rhinovirus 14 pretreated with compound for 1 hr followed by viral infection measured by MTT assay Cytotoxicity against human H1-HeLa cells infected with 1 MOI human rhinovirus 14 pretreated with compound for 1 hr followed by viral infection measured by MTT assay	[PMID: 38389877]
H1-HeLa	CC₅₀	>100 μM Compound: Rupintrivir	Cytotoxicity against human H1-HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human H1-HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 39032404]
HeLa	CC₅₀	>100 μM Compound: 9	Cytotoxicity against uninfected H1HeLa cells Cytotoxicity against uninfected H1HeLa cells	[PMID: 11591501]
HeLa	EC₅₀	0.005 μM Compound: 9	Anti viral activity against human rhinovirus (HRV) in H1HeLa cells Anti viral activity against human rhinovirus (HRV) in H1HeLa cells	[PMID: 11591501]
HeLa	EC₅₀	0.012 μcm Compound: AG-7088	Antiviral activity against HRV2 in HeLa cells Antiviral activity against HRV2 in HeLa cells	[PMID: 18248816]
HeLa	EC₅₀	0.012 μM Compound: AG-7088	Antiviral activity against HRV2 in HeLa cells Antiviral activity against HRV2 in HeLa cells	[PMID: 18248816]
HeLa	EC₅₀	0.27 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVA16 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus CVA16 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	0.36 μM Compound: AG-7088	Antiviral activity against Human enterovirus Echo9 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus Echo9 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	0.372 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB4 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus CVB4 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	0.561 μM Compound: AG-7088	Antiviral activity against Human enterovirus EV71 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus EV71 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	0.783 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB2 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus CVB2 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	1.247 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB1 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay Antiviral activity against Human enterovirus CVB1 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	[PMID: 19015331]
HeLa	EC₅₀	1.2 ng/mL Compound: Rupintrivir	Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	1.2 ng/mL Compound: Rupintrivir	Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	1.5 ng/mL Compound: Rupintrivir	Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	2 ng/mL Compound: Rupintrivir	Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	2 ng/mL Compound: Rupintrivir	Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	3 ng/mL Compound: Rupintrivir	Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	CC₅₀	>50 μM Compound: Rupintrivir	Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by SRB assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by SRB assay	[PMID: 30676026]
RD	EC₅₀	0.009 μM Compound: 2H; AG7088	Antiviral activity against Enterovirus 71/Shenzhen/120F1/09 infected in human RD cells assessed as reduction in virus induced cell death after 72 hrs by CCK-8 assay Antiviral activity against Enterovirus 71/Shenzhen/120F1/09 infected in human RD cells assessed as reduction in virus induced cell death after 72 hrs by CCK-8 assay	[PMID: 27234148]
RD	CC₅₀	>1 μM Compound: Rupintrivir	Cytotoxicity against human RD cells by MTS assay Cytotoxicity against human RD cells by MTS assay	[PMID: 36455356]
RD	CC₅₀	>100 μM Compound: Rupintrivir	Cytotoxicity against human RD cells Cytotoxicity against human RD cells	[PMID: 38377828]
Vero	EC₅₀	0.419 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVA16 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus CVA16 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]
Vero	EC₅₀	0.481 μM Compound: AG-7088	Antiviral activity against Human enterovirus Echo9 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus Echo9 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]
Vero	EC₅₀	0.791 μM Compound: AG-7088	Antiviral activity against Human enterovirus EV71 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus EV71 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]
Vero	EC₅₀	0.843 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB4 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus CVB4 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]
Vero	EC₅₀	0.982 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB2 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus CVB2 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]
Vero	EC₅₀	1.725 μM Compound: AG-7088	Antiviral activity against Human enterovirus CVB1 infected in Vero cells after 4 to 7 days by plaque reduction assay Antiviral activity against Human enterovirus CVB1 infected in Vero cells after 4 to 7 days by plaque reduction assay	[PMID: 19015331]
Vero	CC₅₀	>50 μM Compound: Rupintrivir	Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 2 days by SRB assay Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 2 days by SRB assay	[PMID: 30676026]
Vero	IC₅₀	6.6 μM Compound: Rupintrivir	Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 2 days by SRB staining based microscopic method Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 2 days by SRB staining based microscopic method	[PMID: 30676026]

In Vitro

In H1-HeLa and MRC-5 cell protection assays, Rupintrivirvr (AG7088) inhibited the replication of all HRV serotypes (48 of 48) tested with a mean 50% effective concentration (EC₅₀) of 0.023 μM (range, 0.003 to 0.081 μM) and a mean EC₉₀ of 0.082 μM (range, 0.018 to 0.261 μM) as well as that of related picornaviruses including coxsackieviruses A21 and B3, enterovirus 70, and echovirus 11^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rupintrivirvr (AG7088) reduces RV-induced TH-2 cytokine IL-4 in precision-cut lung slices (PCLS) of HDM-sensitized mice ex vivo^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 223537-30-2
Appearance Solid
Peso molecular 598.66
Fòrmula C₃₁H₃₉FN₄O₇
Color White to off-white
SMILES

O=C(OCC)/C=C/[C@@H](NC([C@H](CC1=CC=C(F)C=C1)CC([C@@H](NC(C2=NOC(C)=C2)=O)C(C)C)=O)=O)C[C@H]3C(NCC3)=O
Synonyms

AG7088
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (7)

All

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
J Virol

Modeling human enterovirus A71 infection using an intestinal microphysiological system. [Abstract]

2026 May 19;100(5):e0025026. PMID: 42012182
Microbiol Spectr

Potent small molecule inhibitors against the 3C protease of foot-and-mouth disease virus. [Abstract]

2024 Apr 2;12(4):e0337223. PMID: 38466127
Viruses

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]

2020 Jun 10;12(6):628. PMID: 32532085
Arch Virol

Identification of cryptic putative IRESs within the ORF encoding the nonstructural proteins of the human rhinovirus 16 genome. [Abstract]

2021 Dec;166(12):3373-3386. PMID: 34608523
Patent

US20210308117A1.
Research Square Preprint

2021 Mar.

Solvente y solubilidad

In Vitro:

DMSO : 50 mg/mL (83.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6704 mL

8.3520 mL

16.7040 mL

5 mM

0.3341 mL

1.6704 mL

3.3408 mL

10 mM

0.1670 mL

0.8352 mL

1.6704 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Patick AK, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 1999 Oct;43(10):2444-50. [Content Brief]

[2]. Danov O, et al. Rupintrivir reduces RV-induced TH-2 cytokine IL-4 in precision-cut lung slices (PCLS) of HDM-sensitized mice ex vivo. Respir Res. 2019 Oct 22;20(1):228. [Content Brief]

[3]. Dragovich PS, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem. 1999 Apr 8;42(7):1203-12. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6704 mL	8.3520 mL	16.7040 mL	41.7599 mL
	5 mM	0.3341 mL	1.6704 mL	3.3408 mL	8.3520 mL
	10 mM	0.1670 mL	0.8352 mL	1.6704 mL	4.1760 mL
	15 mM	0.1114 mL	0.5568 mL	1.1136 mL	2.7840 mL
	20 mM	0.0835 mL	0.4176 mL	0.8352 mL	2.0880 mL
	25 mM	0.0668 mL	0.3341 mL	0.6682 mL	1.6704 mL
	30 mM	0.0557 mL	0.2784 mL	0.5568 mL	1.3920 mL
	40 mM	0.0418 mL	0.2088 mL	0.4176 mL	1.0440 mL
	50 mM	0.0334 mL	0.1670 mL	0.3341 mL	0.8352 mL
	60 mM	0.0278 mL	0.1392 mL	0.2784 mL	0.6960 mL
	80 mM	0.0209 mL	0.1044 mL	0.2088 mL	0.5220 mL

Keywords

Rupintrivir

7 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Rupintrivir

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Human Metabolite Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Rupintrivir

Actividad biológica

Chemical Information

Publications (7)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Rupintrivir

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Human Metabolite Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Rupintrivir

Actividad biológica

Chemical Information

Publications (7)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Rupintrivir Related Classifications

Referencia número: HY-106161